Heart Metabolics Gets Series A Funding
Heart Metabolics Limited, the UK-based developer of a drug to treat heart failure for hypertrophic cardiomyopathy patients, closed a $4 million Series A round from investors including the Trans Tasman Commercialisation Fund in Melbourne, Australia and AshHill Investments, based in the U.S. Heart Metabolics also announced changes to its board as part of the financing.
4 January 2013•3 mins read
